Pitcairn’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-28,940
| Closed | -$6.7M | – | 3 |
|
|
2025
Q3 | $6.7M | Sell |
28,940
-3,417
| -11% | -$696K | 0.53% | 30 |
|
|
2025
Q2 | $6.01M | Sell |
32,357
-3,342
| -9% | -$621K | 0.39% | 45 |
|
|
2025
Q1 | $7.48M | Sell |
35,699
-27
| -0.1% | -$5.25K | 0.45% | 36 |
|
|
2024
Q4 | $6.35M | Sell |
35,726
-546
| -2% | -$100K | 0.37% | 44 |
|
|
2024
Q3 | $7.16M | Sell |
36,272
-2,282
| -6% | -$426K | 0.42% | 41 |
|
|
2024
Q2 | $6.61M | Buy |
38,554
+1,926
| +5% | +$319K | 0.4% | 40 |
|
|
2024
Q1 | $6.67M | Sell |
36,628
-933
| -2% | -$161K | 0.43% | 41 |
|
|
2023
Q4 | $5.82M | Buy |
37,561
+1,058
| +3% | +$154K | 0.43% | 38 |
|
|
2023
Q3 | $5.44M | Buy |
36,503
+9,147
| +33% | +$1.34M | 0.45% | 36 |
|
|
2023
Q2 | $3.69M | Sell |
27,356
-3,051
| -10% | -$447K | 0.31% | 45 |
|
|
2023
Q1 | $4.85M | Buy |
30,407
+792
| +3% | +$121K | 0.45% | 33 |
|
|
2022
Q4 | $4.79M | Buy |
29,615
+983
| +3% | +$151K | 0.48% | 32 |
|
|
2022
Q3 | $3.84M | Buy |
28,632
+292
| +1% | +$41.9K | 0.42% | 36 |
|
|
2022
Q2 | $4.34M | Buy |
28,340
+1,389
| +5% | +$212K | 0.46% | 31 |
|
|
2022
Q1 | $4.37M | Sell |
26,951
-927
| -3% | -$135K | 0.38% | 42 |
|
|
2021
Q4 | $3.77M | Sell |
27,878
-59
| -0.2% | -$6.97K | 0.24% | 61 |
|
|
2021
Q3 | $3.01M | Buy |
27,937
+632
| +2% | +$72.2K | 0.21% | 67 |
|
|
2021
Q2 | $3.08M | Sell |
27,305
-595
| -2% | -$67K | 0.21% | 63 |
|
|
2021
Q1 | $3.02M | Buy |
27,900
+1,067
| +4% | +$114K | 0.21% | 68 |
|
|
2020
Q4 | $2.88M | Sell |
26,833
-972
| -3% | -$93.4K | 0.22% | 70 |
|
|
2020
Q3 | $2.44M | Sell |
27,805
-5,443
| -16% | -$512K | 0.21% | 72 |
|
|
2020
Q2 | $3.27M | Buy |
33,248
+4,453
| +15% | +$392K | 0.31% | 47 |
|
|
2020
Q1 | $2.19M | Sell |
28,795
-2,600
| -8% | -$221K | 0.26% | 59 |
|
|
2019
Q4 | $2.78M | Sell |
31,395
-3,053
| -9% | -$253K | 0.26% | 56 |
|
|
2019
Q3 | $2.61M | Buy |
34,448
+527
| +2% | +$36.1K | 0.26% | 53 |
|
|
2019
Q2 | $2.47M | Buy |
33,921
+9,718
| +40% | +$764K | 0.25% | 57 |
|
|
2019
Q1 | $1.95M | Buy |
24,203
+3,532
| +17% | +$289K | 0.21% | 65 |
|
|
2018
Q4 | $1.91M | Buy |
20,671
+1,728
| +9% | +$152K | 0.21% | 66 |
|
|
2018
Q3 | $1.79M | Sell |
18,943
-4,954
| -21% | -$470K | 0.19% | 72 |
|
|
2018
Q2 | $2.21M | Sell |
23,897
-131
| -0.5% | -$12.8K | 0.24% | 56 |
|
|
2018
Q1 | $2.27M | Buy |
24,028
+443
| +2% | +$48.7K | 0.24% | 50 |
|
|
2017
Q4 | $2.28M | Buy |
23,585
+5,849
| +33% | +$551K | 0.23% | 56 |
|
|
2017
Q3 | $1.58M | Sell |
17,736
-1,142
| -6% | -$86.9K | 0.18% | 76 |
|
|
2017
Q2 | $1.37M | Sell |
18,878
-90
| -0.5% | -$6.05K | 0.16% | 84 |
|
|
2017
Q1 | $1.24M | Sell |
18,968
-11
| -0.1% | -$692 | 0.15% | 103 |
|
|
2016
Q4 | $1.19M | Sell |
18,979
-842
| -4% | -$51.4K | 0.15% | 108 |
|
|
2016
Q3 | $1.25M | Sell |
19,821
-903
| -4% | -$58.5K | 0.16% | 98 |
|
|
2016
Q2 | $1.28M | Buy |
20,724
+529
| +3% | +$32.2K | 0.16% | 93 |
|
|
2016
Q1 | $1.15M | Buy |
20,195
+627
| +3% | +$34.9K | 0.15% | 122 |
|
|
2015
Q4 | $1.16M | Buy |
19,568
+495
| +3% | +$28.5K | 0.13% | 124 |
|
|
2015
Q3 | $1.04M | Sell |
19,073
-829
| -4% | -$54K | 0.14% | 125 |
|
|
2015
Q2 | $1.34M | Buy |
19,902
+1,093
| +6% | +$71.4K | 0.15% | 120 |
|
|
2015
Q1 | $1.1M | Sell |
18,809
-520
| -3% | -$31.4K | 0.12% | 134 |
|
|
2014
Q4 | $1.26M | Buy |
19,329
+454
| +2% | +$28.6K | 0.14% | 130 |
|
|
2014
Q3 | $1.09M | Buy |
18,875
+1,172
| +7% | +$65.1K | 0.12% | 142 |
|
|
2014
Q2 | $999K | Sell |
17,703
-1,479
| -8% | -$77.6K | 0.11% | 151 |
|
|
2014
Q1 | $986K | Sell |
19,182
-1,069
| -5% | -$54K | 0.11% | 155 |
|
|
2013
Q4 | $1.07M | Buy |
20,251
+11,857
| +141% | +$583K | 0.12% | 145 |
|
|
2013
Q3 | $376K | Buy |
8,394
+385
| +5% | +$17.1K | 0.05% | 307 |
|
|
2013
Q2 | $331K | Buy |
+8,009
| New | +$350K | 0.04% | 328 |
|
Other funds holding ABBV
Pitcairn's ABBV Position: Q4 2025 in Review
Pitcairn sold out of AbbVie (ABBV) in Q4 2025, closing a stake of 28,940 shares — an estimated $6.7M sold.
Pitcairn first reported a position in ABBV in Q2 2013 and held it in 50 quarters. The position peaked at $7.48M in Q1 2025. 4,145 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.
- Pitcairn reported no remaining AbbVie position as of Q4 2025 after selling out during the quarter.
- Pitcairn sold 28,940 AbbVie shares in Q4 2025, an estimated $6.7M.
- Pitcairn first reported a position in AbbVie in Q2 2013 and held it in 50 quarters.
- Pitcairn's AbbVie position peaked at $7.48M in Q1 2025.
- 4,145 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.
Based on Pitcairn's 13F filing for Q4 2025.